Get the Stockscreener App
0.285
13.50%
0.0339
After Hours:
.29
0.005
+1.75%
VolitionRX Ltd stock is traded at $0.285, with a volume of 6.56M.
It is up +13.50% in the last 24 hours and up +13.64% over the past month.
VolitionRX Limited, a life sciences company, engages in the development of blood tests to help diagnose a range of cancers worldwide. The company develops 39 epigenetic Nu.Q blood assays based on its Nucleosomics biomarker discovery platform. VolitionRX Limited is based in Singapore.
See More
Previous Close:
$0.2511
Open:
$0.2798
24h Volume:
6.56M
Relative Volume:
2.93
Market Cap:
$35.00M
Revenue:
$1.29M
Net Income/Loss:
$-29.87M
P/E Ratio:
-0.7917
EPS:
-0.36
Net Cash Flow:
$-14.70M
1W Performance:
+1.06%
1M Performance:
+13.64%
6M Performance:
-59.40%
1Y Performance:
-54.40%
1-Day Range:
$0.266
$0.3149
1-Week Range:
$0.25
$0.3149
52-Week Range:
$0.22
$0.94
VolitionRX Ltd Stock (VNRX) Company Profile
Name
VolitionRX Ltd
Sector
Industry
Phone
646 650 1351
Address
No. 24-05 Shaw Centre, 1 Scotts Road, Singapore, TX
Compare VNRX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
VNRX
VolitionRX Ltd
|
0.285 | 30.84M | 1.29M | -29.87M | -14.70M | -0.36 |
|
TMO
Thermo Fisher Scientific Inc
|
578.61 | 222.48B | 44.56B | 6.73B | 6.29B | 17.74 |
|
DHR
Danaher Corp
|
218.89 | 155.25B | 24.57B | 3.60B | 5.25B | 5.0475 |
|
IDXX
Idexx Laboratories Inc
|
670.46 | 54.04B | 4.17B | 1.03B | 940.22M | 12.61 |
|
IQV
Iqvia Holdings Inc
|
230.15 | 40.13B | 15.90B | 1.28B | 2.21B | 7.2842 |
|
A
Agilent Technologies Inc
|
133.85 | 37.78B | 6.95B | 1.30B | 1.15B | 4.5696 |
VolitionRX Ltd Stock (VNRX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-08-25 | Initiated | H.C. Wainwright | Buy |
| Feb-01-23 | Downgrade | The Benchmark Company | Buy → Hold |
| Feb-17-22 | Resumed | Cantor Fitzgerald | Overweight |
| Mar-10-21 | Initiated | Cantor Fitzgerald | Overweight |
| May-16-18 | Initiated | Maxim Group | Buy |
| May-14-18 | Reiterated | The Benchmark Company | Buy |
| Sep-07-16 | Reiterated | Rodman & Renshaw | Buy |
| Feb-01-16 | Initiated | Rodman & Renshaw | Buy |
View All
VolitionRX Ltd Stock (VNRX) Latest News
VolitionRx Prepares French Reimbursement Submission for Nu.Q Cancer Blood Tests - citybuzz -
VolitionRx (VNRX) Moves Forward with French Reimbursement Submis - GuruFocus
VolitionRx moves to bring Nu.Q lung cancer test to French patients - Stock Titan
Aug Wrap: Is VolitionRx Limited benefiting from innovation trendsMarket Activity Report & Growth Focused Stock Pick Reports - baoquankhu1.vn
VNRX: D. Boral Capital Maintains Buy Rating and $3 Price Target - GuruFocus
VolitionRx (VNRX) Expands Nu.Q Vet Cancer Test Reach in U.S. and Asia - GuruFocus
Dog cancer blood test expands to all 50 states and parts of Asia - Stock Titan
VolitionRX (VNRX) Receives Buy Rating, Price Target Maintained a - GuruFocus
Why VolitionRx Limited stock is popular among millennialsEarnings Growth Report & Expert Curated Trade Setups - Улправда
Volitionrx stock soars after feline cancer test shows high accuracy By Investing.com - Investing.com Australia
VolitionRx Signs Amended Securities Purchase Agreement With Lind Global Asset Management XII - TradingView — Track All Markets
Is VolitionRx Limited stock trading near support levels2025 Key Lessons & Growth Oriented Trading Recommendations - Улправда
VolitionRx Limited Announces Breakthrough Clinical Data for Nu.Q Vet Cancer Test in Cats - marketscreener.com
VolitionRx secures $2 million in additional funding through convertible note By Investing.com - Investing.com India
VolitionRX announces breakthrough clinical data for Nu.Q® veterinary cancer test in cats - MarketScreener
VolitionRx secures $2M financing through amended securities agreement; shares up - MSN
VolitionRX Ltd enters amended securities purchase agreement - marketscreener.com
VolitionRx Secures $2.0 Million in Funding - Yahoo Finance
VolitionRx Announces Breakthrough Clinical Data for Nu.Q® Vet Cancer Test in Cats - marketscreener.com
A simple blood test that can spot lymphoma in cats may be on the way - Stock Titan
VolitionRx downgraded to Hold from Buy at Maxim - MSN
How buybacks impact VolitionRx Limited stock valueJuly 2025 Update & Entry and Exit Point Strategies - Улправда
How VolitionRx Limited stock performs during Fed tightening cyclesJuly 2025 Pullbacks & Fast Gain Swing Trade Alerts - Улправда
VolitionRX (VNRX) Target Price Slashed by D. Boral Capital | VNR - GuruFocus
Simple blood tests for cancer and sepsis move closer to hospitals in 2025 - Stock Titan
VolitionRx announces new paper on Capture-Seq, achieves 180-fold enrichment - MSN
VolitionRx to eliminate veterinary CEO role as part of cost-realignment - Investing.com Australia
VolitionRx Announces Termination of CEO Position at Subsidiary - TradingView — Track All Markets
VolitionRx (VNRX) to end Volition Veterinary CEO role, retain Dr. Butera as consultant - Stock Titan
VolitionRx (VNRX) Unveils Innovative Cancer Detection Method - GuruFocus
Volition (NYSE AMERICAN: VNRX) posts 100% sensitivity in 70-person liquid biopsy study - Stock Titan
VolitionRx’s (VNRX) “Buy” Rating Reaffirmed at D. Boral Capital - Defense World
Why VolitionRX Limited stock is a strong buy call2025 Pullback Review & Risk Controlled Daily Plans - Newser
VolitionRx’s Sepsis Biomarker Selected for French National Healthcare Initiative - citybuzz
VolitionRX (VNRX): Analyst Maintains 'Buy' Rating Amidst Stable Price Target | VNRX Stock News - GuruFocus
VolitionRx (NYSE AMERICAN: VNRX) named sole biomarker partner in €6.3M DETECSEPS sepsis detection program - Stock Titan
How VolitionRx Limited stock valuations compare to rivalsGap Up & Fast Entry Momentum Trade Alerts - Newser
VolitionRx (NYSE:VNRX) Lowered to “Hold” Rating by Maxim Group - Defense World
How VolitionRx Limited stock reacts to job market data2025 Market Sentiment & Consistent Growth Equity Picks - Newser
VNRX: Maxim Group Downgrades VolitionRX to Hold | VNRX Stock New - GuruFocus
Healthy Upside Potential: VolitionRX Ltd (VNRX) - Setenews
VolitionRx (VNRX) Insider Trading Activity 2025 - MarketBeat
Why millennials buy VolitionRX Limited stockQuarterly Earnings Summary & AI Optimized Trade Strategies - moha.gov.vn
VolitionRX (VNRX) Analyst Rating Update: Maintain 'Buy' with $5 Target | VNRX Stock News - GuruFocus
VolitionRX Ltd (VNRX) is looking forward to a strong quarter - Setenews
VolitionRx (VNRX) Stock Surges with First Sale of Nu.Q Cancer Assays to European Cancer Center - parameter.io
VolitionRx announces first sale of Nu.Q Cancer assays to French hospital - Investing.com India
VolitionRx announces first sale of Nu.Q Cancer assays to French hospital By Investing.com - Investing.com South Africa
Nu.Q Cancer Assays Sold for Certification at Lyon Center, VolitionRx (NYSE: VNRX) - Stock Titan
Freedom Capital Markets lowers VolitionRX stock price target on delayed revenue growth - Investing.com Australia
Freedom Capital Markets lowers VolitionRX stock price target on delayed revenue growth By Investing.com - Investing.com South Africa
VolitionRX Ltd Stock (VNRX) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.19%
0.63%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):